

Rec'd PCT/PTO 06 APR 2005

PCT/GB/003/00 4250



INVESTOR IN PEOPLE

The Patent Office

Concept House

Cardiff Road

Newport

South Wales

NP10 8QQ

REC'D 06 NOV 2003

PCT


10/530450

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*Andrew Gensley*

Dated


29 October 2003

Best Available Copy

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Patents Form 1/77

Patents Act 1977  
(Rule 16)

The  
Patent  
Office

07OCT02 E753750-1 D02973  
P01/7700 0.00-0223187.6**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP9 1RH

**1. Your reference**

P101116GB

**2. Patent application number**

(The Patent Office will fill in this part)

0223187.6

- 7 OCT 2002

**3. Full name, address and postcode of the or of each applicant (underline all surnames)**

Ludwig Institute for Cancer Research  
Postfach 8024  
ZURICH  
Switzerland

Patents ADP number (if you know it)

577155002

If the applicant is a corporate body, give the country/state of its incorporation

**4. Title of the invention**

Screen

**5. Name of your agent (if you have one)**

Harrison Goddard Foote

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

31 St Saviourgate  
YORK  
YO1 8NQ

Patents ADP number (if you know it)

~~19571001~~

7914237002

**6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number**

Country

Priority application number  
(if you know it)Date of filing  
(day / month / year)**7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application**

Number of earlier application

Date of filing  
(day / month / year)**8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer Yes if)**

- a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
See note (d)

yes

Patents Form 1/77

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	14
Claim(s)	7
Abstract	1
Drawing(s)	10

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature *Harrison Goddard for* Date *7 October 2002*

12. Name and daytime telephone number of person to contact in the United Kingdom

Robert C Docherty

01904 732120

**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

### SCREEN

The invention relates to a screening method to determine the susceptibility of a mammal, preferably a human, to abnormal development of the nervous system and including therapeutic methods and compositions for the treatment of neurodegenerative conditions which result in abnormal expression of a family of polypeptides which induce the apoptotic function of p53.

Apoptosis, or programmed cell death, is a process by which multi-cellular organisms regulate cell number and differentiation. The process is regulated by factors which either induce or prevent apoptosis. Inducers of apoptosis include Bcl-2 family members, caspase family members and their associated factors Apaf-1 and Fadd. Caspases are synthesised as proenzymes which become activated after proteolytic cleavages. The active caspase then induces many of the morphological and biochemical changes associated with apoptosis. Mitochondria play a pivotal role in the activation process through the release of pro-apoptotic factors such as cytochrome c, AIF and Diablo. The release from mitochondria is controlled by the Bcl-2 family of proteins; (e.g. Bcl-2 and Bcl-xl inhibit release; Bax and Bak induce release). WO9953051 discloses a cytokine dependent protein p21 which has pro-apoptotic activity. p21 is expressed in a cytokine dependent manner in myeloid/erythroid cells. These cells are dependent on IL-3 for growth and in the absence of IL-3 the translation of p21 is induced resulting in apoptosis and cell death. p21 is a cytoplasmic protein which translocates to the outer mitochondrial membrane to induce pro-apoptotic activities.

25

Tumour suppressor proteins also have pro-apoptotic activities.

Tumour suppressor genes encode proteins which function to inhibit cell growth or division and are therefore important with respect to maintaining proliferation, growth and differentiation of normal cells. Mutations in tumour suppressor genes result in abnormal cell-cycle progression whereby the normal cell-cycle check points which

30

arrest the cell-cycle, when, for example, DNA is damaged, are ignored and damaged cells divide uncontrollably. The products of tumour suppressor genes function in all parts of the cell (e.g. cell surface, cytoplasm, nucleus) to prevent the passage of damaged cells through the cell-cycle (i.e. G1, S, G2, M and cytokinesis).

5

Arguably the tumour suppressor gene which has been the subject of the most intense research is p53. p53 encodes a protein which functions as a transcription factor and is a key regulator of the cell division cycle. It was discovered in 1978 as a protein shown to bind with affinity to the SV40 large T antigen. The p53 gene encodes a 393 amino acid polypeptide with a molecular weight of 53kDa. Genes regulated by the transcriptional activity of p53 contain a p53 recognition sequence in their 5' regions. These genes are activated when the cellular levels of p53 are elevated due to, for example DNA damage. Examples of genes which respond to p53 include, mdm2, Bax and PIG-3. Bax and PIG-3 are involved in one of the most important functions of p53, the induction of apoptosis.

10  
15

In our co-pending application WO02/12325 we disclose, amongst other things, a new family of pro-apoptotic polypeptides which regulate the apoptotic activity of p53. We herein describe the involvement of this family in the development of the central nervous system (CNS) in mammals. Neonatal mice which are homozygous null for the ASPP 2 gene have abnormal development of the CNS. The cells of the CNS have abnormal patterns of division which results in abnormalities, particularly in the brain and retina, of developing neonatal mice. This is suggestive of the need for programmed cell death in the differentiation of the CNS and the involvement of the ASPP 2 family in regulating this process.

20  
25

According to an aspect of the invention there is provided a method for the detection of a polypeptide in a cell or tissue sample which sample comprises a nerve cell or a nerve progenitor cell and wherein said polypeptide is a polypeptide which induces the apoptotic function of p53.

30

In a preferred method of the invention said polypeptide is selected from the group consisting of:

- a) a polypeptide encoded by a nucleic acid molecule as represented by the sequence shown in Figure 1 or 2;
- 5 b) a polypeptide encoded by a nucleic acid molecule which hybridises to the nucleic acid molecule in (a); or
- c) a polypeptide encoded by a nucleic acid molecule which is degenerate because of the genetic code to the nucleic acid molecule represented in (a) and (b); said method comprising the steps of;
- 10 i) providing a sample comprising a nerve cell or a nerve cell progenitor cell;
- ii) contacting said sample with an agent which binds said polypeptide;
- iii) detecting the presence of said polypeptide in said cell sample.

15 In a preferred method of the invention said polypeptide is encoded by a nucleic acid molecule which hybridises under stringent hybridisation conditions to the nucleic acid sequence as represented in Figure 1 or 2. Preferably said nucleic acid is represented by the nucleic acid sequence in Figure 1 or 2.

20 In a preferred embodiment of the invention said polypeptide is represented by the amino acid sequences in Figures 3 or 4 wherein said polypeptide is altered by addition, deletion or substitution of at least one amino acid residue.

25 In a preferred method of the invention said agent is an antibody which binds said polypeptide; preferably a polyclonal antibody.

In a further preferred method of the invention said antibody is a monoclonal antibody.

30 In a yet further preferred method of the invention said antibody is provided with means which enable the detection, either directly or indirectly, of the antibody bound to said polypeptide.

In a preferred method of the invention said detection means is selected from the group consisting of: an enzyme; a isotope label or a fluorescent label.

- 5 In an alternative preferred method of the invention said method is the detection of a nucleic acid molecule which encodes said polypeptide.

In an alternative preferred method of the invention said agent is a nucleic acid molecule adapted to anneal to said nucleic acid molecule which encodes said  
10 polypeptide.

In a preferred method of the invention said nucleic acid molecule is at least one oligonucleotide molecule. Preferably a pair of oligonucleotide molecules adapted to bind said nucleic acid molecule which is to be detected. Preferably said method is a  
15 polymerase chain reaction method.

According to a further aspect of the application there is provided the use of a polypeptide selected from the group consisting of:

- 20 i) a polypeptide encoded by a nucleic acid molecule as represented by the sequence shown in Figure 1 or 2;
- ii) a polypeptide encoded by a nucleic acid molecule which hybridises to the nucleic acid molecule in (i); or
- 25 iii) a polypeptide encoded by a nucleic acid molecule which is degenerate because of the genetic code to the nucleic acid molecule represented in (i) and (ii).

for use in the manufacture of a medicament for use in the treatment of neurodegenerative diseases which result from a deficiency in said polypeptide.

30 In a preferred embodiment of the invention said polypeptide is represented by the amino acid sequence presented in Figure 3 or 4 wherein said sequence has been modified by addition, deletion or substitution of at least one amino acid residue.

We disclose that mice which do not express ASPP family members show abnormal neural development in the neonatal CNS and retina as a result of uncontrolled cell division. This strongly implicates ASPP induced apoptosis in the development of the  
5 CNS. In addition there are a number of neurodegenerative diseases in which apoptosis is implicated. For example, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. It is possible that inappropriate expression of ASPP family members in these conditions could result in premature cell death of neurones. This theory is readily testable by methods established in the art.

10

In a preferred embodiment of the invention said polypeptide is encoded by a nucleic acid molecule. Preferably said nucleic acid molecule is part of a vector adapted for gene therapy.

15 The invention also contemplates gene therapy of neurodegenerative diseases. The procedure for performing *ex vivo* gene therapy is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction *in vitro* of a functional copy of a gene into a cell(s) of a subject which contains a defective copy of the gene, and  
20 returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application  
25 WO95/00654. *In vivo* gene therapy using vectors such as adenovirus, retroviruses, herpes virus, and targeted liposomes also is contemplated according to the invention.

According to a further aspect of the application there is provided the use of an antagonist which interacts with a polypeptide selected from the group consisting of:

30 i) a polypeptide encoded by a nucleic acid molecule as represented by the sequence shown in Figure 1 or 2;



- ii) a polypeptide encoded by a nucleic acid molecule which hybridises to the nucleic acid molecule in (i); or
- iii) a polypeptide encoded by a nucleic acid molecule which is degenerate because of the genetic code to the nucleic acid molecule represented in (i) and (ii).

5

for use in the manufacture of a medicament for use in the treatment of neurodegenerative diseases which result from abnormal expression of said polypeptide.

- 10 In a preferred embodiment of the invention said polypeptide is represented by the amino acid sequence presented in Figure 3 or 4 wherein said sequence has been modified by addition, deletion or substitution of at least one amino acid residue.

- 15 In a further preferred method of the invention said disease is selected from the group consisting of: Alzheimer's disease; Parkinson's disease; multiple sclerosis; retinopathies.

- 20 In a preferred embodiment of the invention said antagonist is an antibody or antibody part which binds said polypeptide. Preferably said antibody is a monoclonal antibody or binding part thereof.

- 25 Antibodies, also known as immunoglobulins, are protein molecules which usually have specificity for foreign molecules (antigens). Immunoglobulins (Ig) are a class of structurally related proteins consisting of two pairs of polypeptide chains, one pair of light (L) (low molecular weight) chain ( $\kappa$  or  $\lambda$ ), and one pair of heavy (H) chains ( $\gamma$ ,  $\alpha$ ,  $\mu$ ,  $\delta$  and  $\epsilon$ ), all four linked together by disulphide bonds. Both H and L chains have regions that contribute to the binding of antigen and that are highly variable from one Ig molecule to another. In addition, H and L chains contain regions that are non-variable or constant.

30

The L chains consist of two domains. The carboxy-terminal domain is essentially identical among L chains of a given type and is referred to as the "constant" (C) region. The amino terminal domain varies from L chain to L chain and contributes to the binding site of the antibody. Because of its variability, it is referred to as the  
5 "variable" (V) region.

The H chains of Ig molecules are of several classes,  $\alpha$ ,  $\mu$ ,  $\sigma$ ,  $\kappa$ , and  $\gamma$  (of which there are several sub-classes). An assembled Ig molecule consisting of one or more units of two identical H and L chains, derives its name from the H chain that it possesses.  
10 Thus, there are five Ig isotypes: IgA, IgM, IgD, IgE and IgG (with four sub-classes based on the differences in the 'constant' regions of the H chains, i.e., IgG1, IgG2, IgG3 and IgG4). Further detail regarding antibody structure and their various functions can be found in, Using Antibodies: A laboratory manual, Cold Spring Harbour Laboratory Press.

15

In a preferred embodiment of the invention said fragment is a Fab fragment.

In a further preferred embodiment of the invention said antibody is selected from the group consisting of:  $F(ab')_2$ , Fab, Fv and Fd fragments; and antibodies comprising  
20 CDR3 regions.

A modified antibody, or variant antibody, and reference antibody, may differ in amino acid sequence by one or more substitutions, additions, deletions, truncations which may be present in any combination. Among preferred variants are those that  
25 vary from a reference polypeptide by conservative amino acid substitutions. Such substitutions are those that substitute a given amino acid by another amino acid of like characteristics. The following non-limiting list of amino acids are considered conservative replacements (similar): a) alanine, serine, and threonine; b) glutamic acid and aspartic acid; c) asparagine and glutamine d) arginine and lysine; e)  
30 isoleucine, leucine, methionine and valine and f) phenylalanine, tyrosine and

tryptophan. Most highly preferred are variants which show enhanced biological activity.

Preferably said antibody is a humanised or chimeric antibody.

5

A chimeric antibody is produced by recombinant methods to contain the variable region of an antibody with an invariant or constant region of a human antibody.

10 A humanised antibody is produced by recombinant methods to combine the complementarity determining regions (CDRs) of an antibody with both the constant (C) regions and the framework regions from the variable (V) regions of a human antibody.

15 Chimeric antibodies are recombinant antibodies in which all of the V-regions of a mouse or rat antibody are combined with human antibody C-regions. Humanised antibodies are recombinant hybrid antibodies which fuse the complementarity determining regions from a rodent antibody V-region with the framework regions from the human antibody V-regions. The C-regions from the human antibody are also used. The complementarity determining regions (CDRs) are the regions within the N-  
20 terminal domain of both the heavy and light chain of the antibody to where the majority of the variation of the V-region is restricted. These regions form loops at the surface of the antibody molecule. These loops provide the binding surface between the antibody and antigen.

25 Antibodies from non-human animals provoke an immune response to the foreign antibody and its removal from the circulation. Both chimeric and humanised antibodies have reduced antigenicity when injected to a human subject because there is a reduced amount of rodent (i.e. foreign) antibody within the recombinant hybrid antibody, while the human antibody regions do not elicit an immune response. This  
30 results in a weaker immune response and a decrease in the clearance of the antibody. This is clearly desirable when using therapeutic antibodies in the treatment of human

diseases. Humanised antibodies are designed to have less "foreign" antibody regions and are therefore thought to be less immunogenic than chimeric antibodies.

5 In an alternative preferred embodiment of the invention said antagonist is a nucleic acid molecule.

10 In a preferred embodiment of the invention said nucleic acid molecule is selected from the group consisting of an antisense molecule or an inhibitory RNA molecule designed with reference to Figure 1 or 2.

15 As used herein, the term "antisense molecule" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridises under physiological conditions to DNA comprising a particular gene or to an mRNA  
20 transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridisation with the target gene or transcript. Those skilled in the art will recognise that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will  
25 depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridise substantially more to the target sequence than to any other sequence in the target cell under physiological conditions.  
30 Based upon the ASPP-2 nucleic acid sequences provided herein, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesise any of a number of appropriate antisense molecules for use in accordance with the present invention. For example, a "gene walk" comprising a series of oligonucleotides of 15-30 nucleotides spanning the length of ASPP-2 nucleic acid can be prepared, followed by testing for inhibition of the corresponding

ASPP-2 expression. Optionally, gaps of 5-10 nucleotides can be left between the oligonucleotides to reduce the number of oligonucleotides synthesised and tested.

In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although ASPP1/ASPP-2 cDNA sequences are disclosed herein, one of ordinary skill in the art may easily derive the genomic DNA corresponding to these cDNAs. Thus, the present invention also provides for antisense oligonucleotides which are complementary to ASPP1/ASPP-2 genomic DNA. Similarly, antisense to allelic or homologous cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognised methods which may be carried out manually or by an automated synthesiser. They also may be produced recombinantly by vectors.

A recent technique to specifically ablate gene function is through the introduction of double stranded RNA, also referred to as inhibitory RNA (RNAi), into a cell which results in the destruction of mRNA complementary to the sequence included in the RNAi molecule. The RNAi molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule. The RNAi molecule is typically derived from exonic or coding sequence of the gene which is to be ablated.

- Recent studies suggest that RNAi molecules ranging from 100-1000bp derived from coding sequence are effective inhibitors of gene expression. Surprisingly, only a few molecules of RNAi are required to block gene expression which implies the mechanism is catalytic. The site of action appears to be nuclear as little if any RNAi is detectable in the cytoplasm of cells indicating that RNAi exerts its effect during mRNA synthesis or processing.

In a preferred embodiment of the invention there is provided a transcription cassette comprising an nucleic acid sequence operatively linked to a promoter which promoter transcribes said nucleic acid molecule to produce an antisense nucleic acid molecule, said sequence selected from the group consisting of:

- i) a nucleic acid sequence, or part thereof, as represented in Figure 1 or 2;
- ii) a nucleic acid sequence which hybridises to the sense sequence presented in Figure 1 or 2 and which encodes a polypeptide with anti-apoptotic activity.

In a preferred embodiment of the invention said cassette is part of a vector.

In a further preferred embodiment of the invention there is provided a transcription cassette comprising a nucleic acid molecule, or part thereof, selected from the group consisting of:

- i) a nucleic acid molecule represented by the nucleic acid sequence in Figure 1 or 2;
- ii) a nucleic acid molecule which hybridises to the sequence in (i) above and which encodes a polypeptide with anti-apoptotic activity; or
- 5      iii) a nucleic acid molecule which is degenerate because of the genetic code to the sequences defined in (i) and (ii) above; wherein said cassette is adapted such that both sense and antisense nucleic acid molecules are transcribed from said cassette.

- 10      In a preferred embodiment of the invention said cassette is provided with at least two promoters adapted to transcribe both sense and antisense strands of said nucleic acid molecule.

15      In a further preferred embodiment of the invention said cassette comprises a nucleic acid molecule wherein said molecule comprises a first part linked to a second part wherein said first and second parts are complementary over at least part of their sequence and further wherein transcription of said nucleic acid molecule produces an RNA molecule which forms a double stranded region by complementary base pairing of said first and second parts.

20

In a preferred embodiment of the invention said first and second parts are linked by at least one nucleotide base.

- 25      In a preferred embodiment of the invention said first and second parts are linked by 2, 3, 4, 5, 6, 7, 8, 9 or at least 10 nucleotide bases.

- 30      In a further preferred embodiment of the invention the length of the RNAi molecule is between 100bp-1000bp. More preferably still the length of RNAi is selected from 100bp; 200bp; 300bp; 400bp; 500bp; 600bp; 700bp; 800bp; 900bp; or 1000bp. More preferably still said RNAi is at least 1000bp.

In an alternative preferred embodiment of the invention the RNAi molecule is between 15bp and 25bp, preferably said molecule is 21bp.

In a preferred embodiment of the invention said cassette is part of a vector.

5

According to a further aspect of the invention there is provided method to screen for agents which modulate the activity of a polypeptide which induces the apoptotic function of p53 comprising the steps of:

- 10           i)     providing a cell sample comprising a nerve cell or nerve progenitor cell;
- ii)    contacting said sample with an agent to be tested; and
- iii)   monitoring effect of said agent on the presence and/or activity of said polypeptide.

15   In a preferred method of the invention said polypeptide is selected from the group consisting of:

- a) a polypeptide encoded by a nucleic acid molecule as represented by the sequence shown in Figure 1 or 2;
- b) a polypeptide encoded by a nucleic acid molecule which  
20            hybridises to the nucleic acid molecule in (a); or
- c) a polypeptide encoded by a nucleic acid molecule which is  
              degenerate to the nucleic acid molecule represented in (a) and (b).

25   In a further preferred method of the invention said agent is an antagonist of said polypeptide.

In an alternative preferred method of the invention said agent is an agonist of said polypeptide.

30   An embodiment of the invention will now be described by example only and with reference to the following figures:



Figure 1 is a DNA sequence which encodes ASPP1;

Figure 2 is a DNA sequence which encodes ASPP2;

5

Figure 3 is the amino acid sequence of ASPP1;

Figure 4 is the amino acid sequence of ASPP2;

10 Figure 5 illustrates that the percentage of ASPP2 null mice born is normal;

Figure 6 illustrates the malformation of ASPP2 null embryos;

Figure 7 illustrates that ASPP2 null mice die before weaning;

15

Figure 8 illustrates eye malformation in 13.5 day embryos in ASPP2 (+/-) and ASPP2 (+/+) mice;

Figure 9 illustrates brain malformation 13.5 day embryos in ASPP2 (+/-) and ASPP2

20 (+/+) mice; and

Figure 10 illustrates abnormal cell growth in the brain of an ASPP2 null embryo.

25

30

**CLAIMS**

- 1 A method for the detection of a polypeptide in a cell or tissue sample which  
sample comprises a nerve cell or a nerve progenitor cell and wherein said polypeptide  
5 is a polypeptide which induces the apoptotic function of p53.
2. A method according to Claim 1 wherein said polypeptide is selected from the  
group consisting of:
- 10 a) a polypeptide encoded by a nucleic acid molecule as represented by the  
sequence shown in Figure 1 or 2;
- b) a polypeptide encoded by a nucleic acid molecule which hybridises to  
the nucleic acid molecule in (a); or
- c) a polypeptide encoded by a nucleic acid molecule which is degenerate to  
the nucleic acid molecule represented in (a) and (b); said method  
15 comprising the steps of:
- i) providing a sample comprising a nerve cell or a nerve cell progenitor cell;
- ii) contacting said sample with an agent which binds said polypeptide;
- iii) detecting the presence of said polypeptide in said cell sample.
- 20 3. A method according to Claim 2 wherein said polypeptide is encoded by a  
nucleic acid molecule which hybridises under stringent hybridisation conditions to  
the nucleic acid sequence as represented in Figure 1 or 2.
4. A method according to Claim 3 wherein said nucleic acid is represented by  
25 the nucleic acid sequence in Figure 1 or 2.
5. A method according to any of Claims 2-4 wherein said polypeptide is  
represented by the amino acid sequence in Figures 3 and 4 wherein said sequence has  
been modified by addition, deletion or substitution of at least one amino acid residue.  
30

6. A method according to any of Claims 1-5 wherein said agent is an antibody which binds said polypeptide.

7. A method according to Claim 6 wherein said antibody is a polyclonal antibody.

8. A method according to Claim 6 wherein said antibody is a monoclonal antibody.

9. A method according to any of Claims 6-8 wherein said antibody is provided with means which enable the detection of the antibody bound to said polypeptide.

10. A method according to Claim 9 wherein said detection means is selected from the group consisting of: an enzyme; a isotope label or a fluorescent label.

11. A method according to any of Claims 1-5 wherein said method is the detection of a nucleic acid molecule which encodes said polypeptide.

12. A method according to Claim 11 wherein said agent is a nucleic acid molecule adapted to anneal to said nucleic acid molecule which encodes said polypeptide.

13. A method according to Claim 12 wherein said nucleic acid molecule is at least one oligonucleotide molecule.

14. A method according to Claim 13 wherein said nucleic acid molecule is a pair of oligonucleotide molecules adapted to bind said nucleic acid molecule which is to be detected.

15. A method according to Claim 14 wherein said method is a polymerase chain reaction method.

16. The use of a polypeptide selected from the group consisting of:

- 5           i) a polypeptide encoded by a nucleic acid molecule as represented by the sequence shown in Figure 1 or 2;
- ii) a polypeptide encoded by a nucleic acid molecule which hybridises to the nucleic acid molecule in (i); or
- 10          iii) a polypeptide encoded by a nucleic acid molecule which is degenerate because of the genetic code to the nucleic acid molecule represented in (i) and (ii).

for use in the manufacture of a medicament for use in the treatment of neurodegenerative diseases which result from a deficiency in said polypeptide.

15 17. A method according to Claim 16 wherein said polypeptide is encoded encoded by a nucleic acid molecule.

18. A method according to Claim 16 or 17 wherein said polypeptide is represented by the amino acid sequence in Figures 3 and 4 wherein said sequence has  
20 been modified by addition, deletion or substitution of at least one amino acid residue.

19. A method according to Claim 17 wherein said nucleic acid molecule is part of a vector adapted for gene therapy.

25 20. The use of an antagonist which interacts with a polypeptide selected from the group consisting of:

- i) a polypeptide encoded by a nucleic acid molecule as represented by the sequence in Figure 1 or 2;
- ii) a polypeptide encoded by a nucleic acid molecule which  
30 hybridises to the nucleic acid molecule in (i); or

- iii) a polypeptide encoded by a nucleic acid molecule which is degenerate to the nucleic acid molecule represented in (i) and (ii).

for use in the manufacture of a medicament for use in the treatment of neurodegenerative diseases which result from abnormal expression of said polypeptide.

21. Use according to Claim 20 wherein said polypeptide is represented by the amino acid sequence in Figures 3 and 4 wherein said sequence has been modified by addition, deletion or substitution of at least one amino acid residue.

22. Use according to Claim 20 or 21 wherein said disease is selected from the group consisting of: Alzheimer's disease; Parkinson's disease; multiple sclerosis; or a retinopathy.

23. Use according to any of Claims 20-22 wherein said antagonist is an antibody or antibody part which binds said polypeptide.

24. Use according to Claim 23 wherein said antibody is a monoclonal antibody or binding part thereof.

25. Use according to Claim 23 or 24 wherein said fragment is a Fab fragment.

26. Use according to Claim 25 wherein said fragment is selected from the group consisting of: F(ab')<sub>2</sub>, Fab, Fv and Fd fragments; and CDR3 regions.

27. Use according to any of Claims 24-26 wherein said antibody is a humanised.

28. Use according to any of Claims 24-26 wherein said antibody is a chimeric antibody.

29. Use according to Claim 20 wherein said antagonist is a nucleic acid molecule.

5 30. Use according to Claim 29 wherein said nucleic acid molecule is a transcription cassette comprising an nucleic acid molecule operatively linked to a promoter which promoter transcribes said nucleic acid molecule to produce an antisense nucleic acid molecule, said sequence selected from the group consisting of:

- 10 i) a nucleic acid sequence, or part thereof, as represented in Figure 1 or 2;
- ii) a nucleic acid sequence which hybridises to the sense sequence presented in Figure 1 or 2 and which encodes a polypeptide with anti-apoptotic activity.

15 31 Use according to Claim 30 wherein said cassette is part of a vector.

32. Use according to Claim 29 wherein said nucleic acid molecule comprises a transcription cassette wherein said a nucleic acid molecule, or part thereof, selected from the group consisting of:

- 20 i) a nucleic acid molecule represented by the nucleic acid sequence in Figure 1 or 2;
- ii) a nucleic acid molecule which hybridises to the sequences in (i) above and which encodes a polypeptide with anti-apoptotic activity; or
- 25 iii) a nucleic acid molecule which is degenerate as a consequence of the genetic code to the sequences defined in (i) and/or (ii) above; wherein said cassette is adapted such that both sense and antisense nucleic acid molecules are transcribed from said cassette.

30 33. Use according to Claim 32 wherein said cassette is provided with at least two promoters adapted to transcribe both sense and antisense strands of said nucleic acid molecule.

34. Use according to Claim 32 wherein said cassette comprises a nucleic acid molecule wherein said molecule comprises a first part linked to a second part wherein said first and second parts are complementary over at least part of their sequence and further wherein transcription of said nucleic acid molecule produces an RNA molecule which forms a double stranded region by complementary base pairing of said first and second parts.
35. Use according to Claim 34 wherein said first and second parts are linked by at least one nucleotide base.
36. Use according to Claim 35 wherein said first and second parts are linked by 2, 3, 4, 5, 6, 7, 8, 9 or at least 10 nucleotide bases.
37. Use according to any of Claims 32-36 wherein the length of said RNAi molecule is between 100bp-1000bp.
38. Use according to Claim 37 wherein the length of said RNAi molecule is selected from at least 100bp; 200bp; 300bp; 400bp; 500bp; 600bp; 700bp; 800bp; 900bp; or 1000bp.
39. Use according to any of Claims 32-36 wherein said RNAi is at least 1000bp in length.
40. Use according to any of Claims 32-36 wherein said RNAi molecule is between 15bp and 25bp in length.
41. Use according to Claim 40 wherein said RNAi molecule is 21bp in length.
42. Use according to any of Claims 32-41 wherein said cassette is part of a vector.

43. A method to screen for agents which modulate the activity of a polypeptide which induces the apoptotic function of p53 comprising the steps of:

- iv) providing a cell sample comprising a nerve cell or nerve progenitor cell;
- v) contacting said sample with an agent to be tested; and
- vi) monitoring effect of said agent on the presence and/or activity of said polypeptide.

44. A method according to Claim 43 wherein said polypeptide is selected from the group consisting of:

- d) a polypeptide encoded by a nucleic acid molecule as represented by the sequence shown in Figure 1 or 2;
- e) a polypeptide encoded by a nucleic acid molecule which hybridises to the nucleic acid molecule in (a); or
- f) a polypeptide encoded by a nucleic acid molecule which is degenerate to the nucleic acid molecule represented in (a) and (b).

44. A method according to Claim 43 or 44 wherein said agent is an antagonist of said polypeptide.

45. A method according to Claim 43 or 44 wherein said agent is an agonist of said polypeptide.



AbstractScreen

5 The invention relates to a screening method to determine the susceptibility of a mammal, preferably a human, to abnormal development of the nervous system and including therapeutic methods and compositions for the treatment of neurodegenerative conditions which result in abnormal expression of a family of polypeptides which induce the apoptotic function of p53.

**Figure 1**

GAGCCCCCATCCCGCCGCGAGCTGCGCGCTCGCGCGCGCGCGCGCGAGAGCACTGGCGCGGAGCGCGCGCTTAGAGGG  
CGCCCGGAGCGGTGGGCAACGCTCGCGCGCGAGAGGCTCTGTCTCAGCGCGCGCGCGCGCGCTCGCGGAGCTCTCCCGCGGAT  
GATCGCGAGATATTAACCTGTCTTTCTGAGCAACATGATACAGATTTTAAACAGAGTCTTATAACACCGGAAACAACT  
GTGAGAGATGTTGTAGAATTTTGCAGGGAACCTGGAGAAGGCACTGCCATTTAGCTGAAGTGTGAAGGGAATGAACCT  
CCCATACGCTTTGATCATATGATATGAGAACATCTTCAGATGTGTGGGCTCCACGGAGGGAGAGAGTGAATTTTTCTCTTC  
ACACAGGAGCTCCCAACACTGAGAACCTGAACAGAGTGGCGCTCAGACCCAGAGCAACGAATCAGAGAAATGTATTA  
ATGTACTCTGCAGATAAACGTAAGTACTGAATATGGGGTTGCGGAATCCACGCTGTGAATCTACCTCTCAGAGCTCCAGATATG  
GCAGCTTAGGCAACAGCGAGAGTGAATATCAGCAGCAGATGTGGTTGTCCAGAGAACAGCGTTACATTTCTTTAAAGCA  
ACAGAGCGCGCTCAGCAGCAGATTTATTTCTGAATAGGAAGCTTCAGAAATGAAGAAACAGATTTGAAGCTCCAGGAGA  
ACAAGCTGAAGAAAATTCGTGCATGAGAGGACAAAGTGGCTACAGCAAAATCATGAACGGCAATCTGTCTGCTGAATAT  
GAAGGCTCTAGTGGCATGTTCCAGAGAAAGAGCAGGAGATACAGACTGCAATTTAAGGGTGTGATCAGCTATGATCAGCA  
ATTGGAAGATTTAAGAAAGGAAACACTGAATGGGTTCCAGTCTTACATAGCGAANTTGAACGGAGCCAGCGCGGCTGAGT  
TAAAGAAGCTGTACCAAGAACTACAGATTCTGTAAACCACTTAACCAAGGAACAAAATTCAAAACCTTCAGCAGCGAGAGGAA  
GTCTTTAAATAGCGCAACATGGAGTGGCCATGATGTGAACAGCGGAATCAGATGAATCGGTGAACCTCTATGGGAAAAA  
AATTCAGCTGAACCGTGTGAATGGCAGCTCATCACCAAGTCCCTCTGAGCAGCATCGGCGAGCGGTGCTGCTGTGTGGCG  
CTTATATCGAGGTTCCCACTGCGCGAAGCTTTCTCTGTGCTGGGGACCTTATAAAGCCCGAGTCTCTCAGTATTGCTCTCA  
ATATGCTGCTCATGGAAGATCCAAATCCGCTATATGATGAACACTGGCCAACTATAAACAGAAATTTAGCTCTTCTCGTGAA  
ACAGCTGAGGTCGCGCGCTGACAGCTGAGAGTTCGAGCTCGGAGGGTGTCTCAGCAGGGGCACTGTCTCCAGCGAGC  
CTGTGCTGCTCTCAGCAGCTGGGACCTCACGAGAGCCGCGCATCGAGATTGCTAAAGTGCACCTCCCATCGCGGCTGT  
GCGAAGCAGCTGCTCTCAGCTATGGGACATCCAGAGTCTTACACTCTGGGTCTGGCTCGCAGACCTCCCTCGGAAG  
GAGGAGGAGAGCGAGTGTGCCCGCGAGTCGAGGCTCCAGATCGACAGAGGCCACCTCTGCTGCTGCGCACAGGCA  
CGACGCTCCAGAGCGAGCTCTCTCAGAACAGATTCAGCAGAGGATTTCCGTACCGCGCAAGTCCCACTGTAACCGGCGGGA  
CCACCTGCAATTTCCAGCTGGGCGCAGCAGCTTGAATCCCATGACAGTGGCCATTTAGGCTTTCTTGGCTGTATTAAGG  
GTCAAGGCCCAAGTCTCCAGGAAGAGGCCAGCAGAGTGAATTCAGTTCATATATCTCCATGTACCTCCAGCAGAGCCA  
CACCACTTAAGAAATTAACGCGCGGCGACACACAGCGCTTAATTAAGTGAATTAAGCAGAGTGTATGTTAAGCCCTTTTA  
CTTGGGTTCAACTCTCCATCGCCCGCTCTGCTCTCTCAAGCGGTCACTGTCCACGGGCAACCAAGGCTCCAGCGACCT  
TTCAAGAAAGTACTGAGAAAGAGGCTGAGCAGAGTGGCCCGCGCGCCCGCAGATGCGAGACCTGGAGAGCTCCGCACT  
GGCCTCTCAGCGCCCAAGCTCAGCGCGATGTGGATTTGGGATTCGCACTCGCTCAGAGAGTGATGAGAGCTTGAAGCCCTC  
CGCAGAGAGCTGGCCCAACGCGCGCGCGCTGAAAGGCGCACTCTCATCAGAGGCGCGAGCGCCCGCGCGCGCCCA  
CATCCAGAGGCTGCTGTACAGCGCTTCAACACCTCGCGCGGTGGCATGAGAGGCACTCTTCTACCAAGCCCACT  
CCAGAGATCTCATGCGCACTGTGGCGGATTTGGAGCAATGGAACACCAATAGCCAAATGGAACCTTGAAGAGAGTCCCGCT  
GCCCGCCCAAGCCCACTCTCGGCTGAGCGTGGCGCTCATCATGATGAATATGATTTACCTTCCCGCGAAC  
AGAGGAGCTCATCTGTATCCCAACCAACCCAGCAAGTCCGAGCGGCGCAGAGCAATACCAACAGCTGGCCACGGCTC  
CCACACCGAGCAGATCCGAGTCTGTGGCTGAGGCGCCCTCTCAGGCGAGAGCGAGGCTCCCTCCAGCAGCTGTTCG  
CTCGCAGCGACCTCTCTCGCATCTGCAAGCAAGCAGCGCACTTAAGAGAGCCCACTCTGGAGCTGACGGGCGCAGG  
GCTGAGAGTCCGGTTTAAACCCCTGGGCACTGCTCTAGACGGCTCTCTGGAAGGAGAGTCTGATCTGGTTCAGAGGATCA  
TCTATGAGGTGGAGATCCGACAGAGCCCAAGCTATGAGGGATCAACCCCATGCAACAGCCCTCTCGCTCGCGGCGACCAT  
CATCTCTGAAGTTCTCTCGGATTTTGGTGTCAAGCTGAATGCTGAGATATGATGAGATGACGCGCTGCTGCTGCTG  
TGCTCTTGTAAACAGGCTTACCTCTGCAACAGCTGCTGGAGTGTGTGCGGCCATTTTTTGCTCTCAACATTAAGCGACA  
TTGAATATGCTGCAGACAAGTGTGAGAGATGAGGATGAGATCATCATGCTCTCCAGTTCTATATGGGGTTCAGAGCA  
AGCTGGGTGTGATGAGAACAAAGCTTGGCGATGCTGTGCGCATCAAGGGGCCAAGTGAACAGTGAACAGCTGTCTCTCA  
CGAGGCGGAGCGCCCTCACATCTGAGCGCGCAAGGACGAAGCCGAGACTGAGTGGTGGTGGGCTCGCTTGGAGACGGGG  
AGGCTATATGTCGCAAAAACCTGCTGGGGCTGTATCGATGATCAAAACCCGACCGCAACACTCGCTCGCTGAACTCTCT  
TTGAGCAACCGCATGCTCTCGCAGCTACAGAGGCGCATTAAGAGATTTATGTGTGTTTTCCAGGAAGCTGCAAGCTAG  
AAAAGGCTCTTAATGGTGTCTACCTTTAGCAGACAGCGTCCACAAATGTGAATCTCACAGTTCCTCAGGTGAGGCCCTTTCTC  
CAGTTTCCCATTAACCTGGGAGAGGTACTTTGGCTCCAGGACTGAATTTTGCATACATATAATTCATATAATATAC  
CCACTTTCAAAGACACCGCTCTTGCTATTAGAGTTCCCAATAACCCCGTGGTGGTTCAGTGAAGCAAGACTCT  
TACTACTTGGCCCGGAGGCGCATCACCCCTCAGGAGTGAACACTGTCCGCGCTGTGAGGCGTGTCTCCCTGCGACCG  
CCCTGCGCCGCTGACCCGATCGGACCTCATCTCTTTGCACTCTCCACACATGATCTCTCTCTCTCATACCAAA  
GGAGCTCTGTATGCAAAACATGTCCAGTGTGTGCGCGGAGTGTATGCTCTCCAGTACCCATCTCTCTGCGCGCTGT  
GGGTTCTCGCTCTCTGTCCAGTTCATTAAGGCTGATTTGCAAGGCGCAGCAGTGGCTGGCTGGAATGCGCGGCGCAAGG  
CHCAGGACCCCTTGAAGCAAGATGAACCTGGGAGAGGCTCAGCATATACCTCTCTCTCTCATCAGGCTGTGATG  
CTGCTCAGTGTGTTCTCACCCCTGCAGCTCAAAATCAATCTCCCTGAATGAGTCAAGTCTGAGAGCGCTGGCAGCGG  
AGGTTGTTGGGTTGGGCTGGGCTGGGCTGGCTGGCTGGGCTGGAGGCGCAGGCTCAGGAGCGCTGGGTTGAGGCGC  
AAGGATGGCAGCGCTGGTGTGAGGAGGGGCGCCACACAGGACAGCAGTGGGCGAGGAGGCTGGGTTGAGGCGC  
ACCCCTCTCTGCGGATCTCCCTGCTGGGCTGGCTGTGTGGGCGCACTTTGCTCCAGGCGCAGGCTCAGGCGAGGCGG  
GCTCTCAGTGGTGTGAATTTGCTACGCTACGGCTTTTATATACCAAAAGTATTTTGTGATGACATTCRAAGTACCG  
GACATATTTTGAATTTTTTTTCTCATTAATAATACAGGCCCTTAGGCTCTATTTTTCATGATGATGATGATGATGAT  
TTATCTAATAATGTCTGTACAGACTCACTGATGCAAGCTGTAGCCCATCAGCTGGAGCACTGATGTACATAGTGTG  
GTGAGAAAGAGTAAAGCCCTTTGAGAGCGCGGCAACAGAGGCACTGCGCTGCCAGCCAGAGGCTGCTGACGCTG  
TGTAAATGTGCACAATAAACCGCTCTCACCGCGA

[illegible]


Figure 3

MMFMILTVFLSNBQIIMTEVPITFETTCDVVEFCKEFGEGSCHLAEVWRGNERIPFDHMMYEBLQIWGPRREEVKFYL  
RHEDSPTENSEQGERQTQEQRTQNVNLNVPDGRTEYGVGNPRVELTSLBLQDMAARQQQIENQQQMLVAKQORLHFLK  
QOERRQQQISISENEKLQKLKBRVBAQENKLIKIRAMRGQVDYSKIMNGWLSABIERFRAMFQEKKEVQTALIRVDQLBQ  
QLBDLKKKGLNGFQSYNGKLTGPAAVBLKRLVQELQIERQILNQEQNSKLQQQKELLNKRMEVAMMDKRISBLRERTYGR  
KIQLNBRVNGTSSPQSPLSTSGRYAARVFPYIQVPSAGSFVVLGDBIKPQSLSLASNAARGSKGANDGNWFTLKQMS88V  
KPVQVAGADWEDPSVEG8VKGQTVSSQPVFFSALQFTEKFGI8IGKVPPPIPGVGKQLPP8YGTYPSPTELGFGSTSSLE  
ARKGSLF8PSAGLFSRQKFTLLPATGSTFQPGSSQIQORI8V88PTYPAGPPAPFAGDSKEBLPLTVAT8FFLAK  
G8LPQS8PRKGFQTVN888IY8MYLQOATPPKNYQPA88BALNK8VKAVYK8VLP8G8TS8PS8LPFLH8SL8T8T8F8Q8F  
P888TEK88F8Q8F8AP8AD8ST8V8SL8PL8PT8K8L8PT8V88PL8YQ8NAD8EAL8RL8L8MAP8PL8KR8S8ITE8F8Q8G8F  
NIQKLLYQ8R8FTL8AG8ME8GT8FP8V8Q8PS8Q8DF8MT8L8AD8VD8NT8AT8G8L8BL8PP8AQ8T8AP8L8AE8F8AP8SD8AND8NEL8P88E  
PEBLICP8QT8TH8QT8AP8ED8NN8NV8TV8PT8EQ8IP8PV8AP8SP8OE8Q8V8P8AP8LP8AS8P8AT8ST8NK8RT8L8K8P888ERT8GH  
GL8VR8FN8PL8ALL8D8AS8L8GE8FD8LV8Q8RI8Y8E8V8ED8PS8KP8ND8EG8IT8PL8T8AV8C8AG8HH8I8VK8FL8D8FG8VM8V8N8AD8SD8G8W8T8PL8HC  
A88C8NS8V8HL8CR8QL8V88CA8IF8AST8I88D8ET8A8DK88E8888GY8IQ8CS8Q8FL8Y8GV8QE8KL8GV8H8KG8V8AY8AL8ND8Y8E8Q8N88DEL8F  
HEGDALATILRRKDE8ET8E8W8K8AR8L8GR8BG8Y8F8KN8LL8GL8Y8PR8IK8P8Q8TL8

Figure 4


MMPHFLTVYLSNNEQHFTEVPVTFETICRDVVDLCKSEGESDCHLAETHCGSERPVADNERMFDVLQRFSGSQNEVRFFL  
RHRPPGGDIYSGPRSQDPSLKHNGVKVGEYRRKENGVSFRMDLTAELOEMASHQQQQTIAQQQLLAATKEORLKFLK  
QQQQRQQQVABQERLKLKLEIAENQEAHLKIVRAIKGHVEQKRLSNQKLVESIEQMMNLFOOKQREIVLAVSKVEELTR  
QLEMLKNGRIDSEHNDQSAVABLDRLYKELQLNNKLNQEQNAKLQQQRECLNENSEVAUNOKRVNELRDRLWKKAALO  
QKENLFVSEDOGLFQQAASAPSEVAAVGPEYIQSSTMPRMEPRPELLVTPALPDGSLVIOASEGPNKIQTLENNRSGAABQ  
TKGSEIHFVGFOWSPSNADLPFSQGSASVFQSTGNALDQVDGGEVFLREKEKEKVRPFPMFDAYDQSNAPPSTGLRKNQ8  
BEDILEDAGVANKNVAKVPPFVPTKPKQINLPYEGQTNQPPSDIKPDGSSQQLSTVVPSEMTKEPKBAGQQQPRVLLSPSIP  
SVGQDQTLSPGSKQBSPPAAAVRPFTPQPSKDTLLPPFRKQPTVAASSIYSMYTOQQAPGKNFQQAUVQSALTKEETRQPH  
FSSVYXKPVLAQAQMQQHPENIYNSQGCPCSPPEPETEEVSSVQENHETRIPRPLSEPKLFFLSMFFYRNQSDADLEA  
LRKKLSNAPAPLKRLSSITEPEGNGPNTQKLLYQRTTIAAMETISVPSYPSKASVTA8888PVEIQNPYLHVEFEKEV  
YSLVFSLSPEFVGNASTENSDMPAPSEGLDYBPEGVEFNSPNLQNMFEFNFPAFVLDVYLEEYPPYPPPPYPSGEP8  
GFGEDSVGNRPFEITGQVSLFPCKRTNLKRTGSEHIAHGNRVKFNPLALLLDSSLEGEFDLVORTIYEVDPPSLPNDGI  
TALHNAVCAHTEIVKPLVQPGVNVNAADSDGWTPLHCAASCNVQVCKFLVB88AAVFAMTYSMDQTEADKCE8MESGY  
TCC8QFLYGVQBKM3IMKGVITYALWDYEFQNDDELPMK8EDCMTI8HREDE8I8W8ARLNDKEGTVP8RLGLYPR1  
KPRQ8SLA

# The percentage of ASPP2 null mice born is normal



*figure 5*

*figure 6*  
**High Frequency of Malformation of ASPP2 Null Embryos**



**E13.5**

**ASPP2**   **-/-**   **-/-**   **-/-**   **+/+**

**figure 6B**



**E16.5**

**(+/+)**

**(-/-)**

**(+/+)**

**(-/-)**

# ASPP2 Null Mice Die Before Weaning

EPIT.



-/-

-/-

-/-


+/+

Figure 7




# Eyes of day 13.5 ASPP2 embryos


---



(-/-)




(+/-)




+/+

*Figure 8*


# Brains of day 13.5 ASPP2 embryos



(-/-)



(+/-)



(+/+)

*Figure 9*

---

## Abnormal growth in the brain of ASPP2 null embryo





Figure 10

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**